CD45RO

CD45RO

CD45RO Molekülinformation

Molecule Name
Leukocyte common antigen
Molekülalias
B220, CD45, CD45R, GP180, IMD105, L-CA, LCA, LY5, T200
Drug Development Progress
Anzahl der klinischen Arzneimittel7
Anzahl der inverkehr gebrachten Arzneimittel0
Höchste Forschungs- und EntwicklungsphasePhase 3 Clinical
Target-Alias
PTPRC,T200,CD45,Protein Tyrosine Phosphatase, Receptor Type C,CD45 Antigen,L-CA,Protein Tyrosine Phosphatase, Receptor Type, C Polypeptide,Receptor-Type Tyrosine-Protein Phosphatase C,T200 Leukocyte Common Antigen,Leukocyte Common Antigen,T200 Glycoprotein,EC 3.1.3.48,CD45R,GP180,B220,LCA,LY5,Leukocyte Common Antigens,Protein Tyrosine Phosphatase Receptor Type C,EC:3.1.3.48

CD45RO Produktliste

Species
  • Human(1)
Tag
  • His Tag(1)
Host
  • HEK293(1)
Conjugate
  • Unconjugated(1)
Grade
  • RUO(1)
Low Endotoxin
  • Yes(1)
MoleculeCat. No.Product NameArtHostStructurePurityActivitySize&PriceAdd to Cart
CD45RO
Human CD45RO Protein, His Tag, low endotoxin (MALS verified)
Human
HEK293
MALSSDS-PAGE

$395.00

100ug
You Have Viewed 1-1 Of 1 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
Immunomodulatory progenitor cell therapy (Celixir)Phase 3 ClinicalCelixir
Cardiomyopathies; Endomyocardial Fibrosis
Details
I-131-ApamistamabBC8-I-131; BC-8; 131IBC8; I-131 BC-8Phase 3 ClinicalFred Hutchinson Cancer Research Center
Anemia, Refractory, with Excess of Blasts; Anemia, Sickle Cell; Anemia, Sideroblastic; Angioimmunoblastic T-cell Lymphoma; Burkitt Lymphoma; Graft vs Host Disease; Hematopoietic stem cell transplantation (HSCT); Hodgkin Disease; Intraocular Lymphoma; Leukemia; Leukemia, Hairy Cell; Leukemia, Large Granular Lymphocytic; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Leukemia-Lymphoma, Adult T-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Lymphomatoid Granulomatosis; Mycosis Fungoides; Myelodysplastic Syndromes; Neoplasms, Gonadal Tissue; Neoplastic Cells, Circulating; Pancytopenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sezary Syndro
Details
At 211 MAb BC8-B10Phase 2 ClinicalFred Hutchinson Cancer Research Center
Neoplasms
Details
211At-BC8-B10211At-BC8-B10Phase 2 ClinicalFred Hutchinson Cancer Research Center, National Cancer Institute
Hematologic Neoplasms; Leukemia; Leukemia, Biphenotypic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Lymphoma; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma
Details
CD45BE-HSPC cells therapy (Kite Pharma)Phase 1 ClinicalKite Pharma
Hodgkin Disease; Lymphoma, B-Cell; Lymphoma, T-Cell; Richter's Syndrome
Details
CART-45 cells therapy (Kite Pharma)Phase 1 ClinicalKite Pharma
Hodgkin Disease; Lymphoma, B-Cell; Lymphoma, T-Cell; Richter's Syndrome
Details
TSC-102TSC-102-A03; TSC-102-A0301; TSC-102; TSC-102-A01Phase 1 ClinicalTScan Therapeutics Inc
Hematologic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma
Details
Customer Reviews